07:35:24 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-08-02 Kvartalsrapport 2024-Q2
2024-07-29 Extra Bolagsstämma 2024
2024-05-27 X-dag ordinarie utdelning BIOWKS 0.00 SEK
2024-05-24 Årsstämma
2024-02-19 Bokslutskommuniké 2023
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-29 X-dag ordinarie utdelning BIOWKS 0.00 SEK
2023-05-26 Årsstämma
2023-02-17 Bokslutskommuniké 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-23 X-dag ordinarie utdelning BIOWKS 0.00 SEK
2022-05-20 Årsstämma
2022-05-06 X-dag ordinarie utdelning BIOWKS 0.00 SEK
2022-02-18 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-24 X-dag ordinarie utdelning BIOWKS 0.00 SEK
2021-05-21 Årsstämma
2021-02-19 Bokslutskommuniké 2020
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-18 X-dag ordinarie utdelning BIOWKS 0.00 SEK
2020-05-15 Årsstämma
2020-02-14 Bokslutskommuniké 2019
2019-10-18 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-27 X-dag ordinarie utdelning BIOWKS 0.00 SEK
2019-05-17 Årsstämma
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-08-19 Kvartalsrapport 2018-Q2
2018-05-21 X-dag ordinarie utdelning BIOWKS 0.00 SEK
2018-05-18 Årsstämma
2018-02-19 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriBioteknik
Bio-Works Technologies är verksamt inom bioteknik. Bolaget utvecklar produkter som separerar och renar molekyler vid framställning av läkemedel. Teknologin baseras på kromatografi som har som avsikt att hantera läkemedelssubstansen. Kunderna återfinns inom den europeiska marknaden där produkterna säljs via distributionspartners och till bolag inom läkemedelsindustrin, samt forskningsinstitut och universitet. Bolaget bildades 2006 och har sitt huvudkontor i Uppsala.
2024-01-02 13:00:00

On December 21 2023, Bio-Works confirmed a new order of WorkBeads, the company's product line for advanced protein purification, to Nemysis Ltd, an Irish developer of bioactive substances designed to target nutritional disorders and deficiencies. The order, worth approximately 2.5 MSEK, will enable Nemysis to scale-up one of its programs to minimize gastrointestinal disorders.

"Bio-Works is very pleased to be able to support Nemysis in its mission to create products which prevent the negative side effects of nutrient disorders and deficiency," said Jonathan Royce, CEO of Bio-Works Technologies. “This order is evidence that our strategy to create unique purification products is in line with the needs of a diversifying platform of biotherapeutic molecules.”

“We have been pleased with the product performance and technical support we have received from Bio-Works during the first production runs for this project, and we are happy to see our partnership continue as we scale-up clinical production during 2024,” said Cristina Comelli, R&D Director at Nemysis Ltd.

Nemysis Ltd is an Irish company focused on development and production of bioactive substances identified as having large market potential, coupled with unmet patient needs, and where it can identify and harness innovative solutions. Nemysis’ therapeutic focus is on nutritional disorders and deficiencies, with particular attention to minimise adverse gastrointestinal side effects, common to existing available solutions.